Anthony Walsh - Sumitomo Dainippon Insider

Sumitomo Dainippon Pharma Co Ltd -- Germany Stock  

EUR 11.44  0.06  0.53%

Independent Director

Mr. Anthony P. Walsh is an Independent Director of Dundee Precious Metals Inc. Mr. Walsh has over 25 years experience in the field of exploration, mining and development. Most recently, Mr. Walsh was President and CEO of Sabina Gold Silver Corporationration from 2008 to 2011, prior to which he served as President and CEO of Miramar Mining Corporationrationration from 1995 to 2007, Senior Vice President and Chief Financial Officer of a computer leasing company from 1993 to 1995 and Chief Financial Officer and Senior Vice President, Finance of International Corona Mines Ltd., a major North American gold producer from 1989 to 1992. Mr. Walsh also serves on the board of directors of several publiclytraded exploration and development companies. Mr. Walsh graduated from Queens University in 1973 and became a member of The Canadian Institute of Chartered Accountants in 1976.
Age: 64  Director Since 2012      

Management Efficiency

The company has return on total asset (ROA) of 4.94 % which means that it generated profit of $4.94 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 7.8 % meaning that it generated $7.8 on every $100 dollars invested by stockholders.
The company has accumulated 628.12 M in total debt with debt to equity ratio (D/E) of 14.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sumitomo Dainippon Pharma Co Ltd has Current Ratio of 1.66 which is within standard range for the sector.

Similar Executives

Entity Summary

Sumitomo Dainippon Pharma Co Ltd (DPM) is traded on Frankfurt Stock Exchange in Germany. and employs 26 people.

Did you try this?

Run Risk-Return Analysis Now
   

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
Hide  View All  Next  Launch Risk-Return Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Sumitomo Dainippon Pharma Co Ltd to your portfolio

Top Management

Sumitomo Dainippon P Leadership Team
Peter Nixon, Director
Richard Gosse, President
Colin McAnuff, Executive
W John, Director, MBA
Richard Howes, President
Garth MacRae, Director
Zebra Kasete, President, MBA
Donald Young, Director
Lori Beak, President
Jeremy Kinsman, Director, MBA
Brent Johnson, President
Paul Proulx, President
Nikolay Hristov, President
Derek Buntain, Director, MBA
Hratch Jabrayan, President
Jonathan Goodman, CEO, MBA
John Lindsay, President
Mark Crawley, President
Peter Gillin, Director
MarieAnne Tawil, Director, MBA
Hume Kyle, President
Anthony Walsh, Director
Juanita Montalvo, Director
David Rae, President
Michael Dorfman, President
Murray John, Director, MBA
R Gillin, Director

Stock Performance

Sumitomo Dainippon Performance Indicators